ClinicalTrials.gg
RecruitingNCT05960929Aero-05Updated Mar 30, 2025

InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS

A Phase 3 interventional study of Infasurf Aero™ in Respiratory Distress Syndrome (Neonatal), Intubation Complication and Death; Neonatal, sponsored by ONY. Recruiting at 10 sites in United States. Open to participants aged 29 Weeks to 36 Weeks. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by ONY · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
29 Weeks to 36 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 43 studies in Pulmonary Atelectasis with a site in United States — 11 open to participants now, 11 under way, 1 of them phase 3. Pulmonary Atelectasis · United States.

Planned enrollment
6th of 37
220 · median 40
Started
2025
with 2 others
Phase 3
Only one
of the 43
Primary completion
2026-01
later than 0 of 10 live
Registered
33rd of 43
by date
Lead sponsor
2 of 43
ONY

Among the 43 studies in Pulmonary Atelectasis with a site in United States, this one is the 6th largest by planned enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2025, is the only one in phase 3, reaches primary completion later than 0 of the 10 other live ones, and was the 33rd registered.

Pulmonary Atelectasis

378 studies on the registry are indexed under Pulmonary Atelectasis; 91 are open to participants now.

Browse Pulmonary Atelectasis studies →

Open to participants now

11 of the 43 studies in Pulmonary Atelectasis with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Pulmonary Atelectasis studies recruiting now, 20 (39%) set no upper age limit and 23 (45%) stop at 75 or younger; 24 take children under 18; 2 take healthy volunteers.

This study: 29 Weeks to 36 Weeks · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Pulmonary Atelectasis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this clinical study is to determine the effectiveness and safety of Infasurf® administered through the InfasurfAero™, a novel oral airway delivery device specifically designed to give Infasurf in a less complicated way and without the need for a breathing tube or interrupting nasal respiratory support.

Read the detailed description

This single-dose, double-blind, random allocation, sham-control, clinical trial will recruit spontaneously breathing newborns with RDS stable on non-invasive nasal respiratory support. Enrolled clinical study subjects will be randomly allocated to receive respiratory air with Infasurf® (Intervention Arm) or respiratory air alone (Sham Control Arm) through the InfasurfAero™.

The objectives of this clinical study are to i) assess the effectiveness of a single dose of Infasurf administered through the InfasurfAero in preventing CPAP failure, and ii) assess the safety of Infasurf administered through the InfasurfAero.

Subjects will be enrolled at one of 10+ sites. 7 sites are currently recruited.

03

Conditions studied

  • Respiratory Distress Syndrome (Neonatal)
  • Intubation Complication
  • Death; Neonatal

Keywords

  • Infasurf
  • Calfactant
  • Inhalation
  • Nebulization
  • Preterm
  • InfasurfAero
  • Respiratory Distress Syndrome
  • Neonatal
  • NICU
  • CPAP
  • Intubation
  • Aerosol
  • CPAP Failure
04

Who can participate

Ages eligible
29 Weeks to 36 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Inclusion criteria include ALL of the following:

  1. Written obtained by parent or legal representative prior to or after birth
  2. Gestational age at birth ≥ 29 0/7 AND ≤ 35 6/7 weeks
  3. Birthweight ≥ 1,000 AND ≤ 3,500 grams
  4. Age ≥ 1 hour AND ≤ 6 hours
  5. Clinical diagnosis of surfactant-deficient RDS, with EITHER i. a Silverman-Anderson Retraction Score ≥ 5 (in Room Air), OR ii. signs of respiratory distress (tachypnea, retractions, grunting) AND radiographic confirmation
  6. Require CPAP
  7. Respiratory Severity Score (RSS) ≥ 1.25 AND ≤ 2.4
  8. If subject is >346/7 weeks' gestation a chest radiograph is required

Exclusion Criteria:

Exclusion criteria are ANY of the following:

  1. Surfactant administration prior to randomization
  2. Mechanical ventilation prior to randomization
  3. Major congenital anomaly (suspected or confirmed)
  4. Abnormality of the airway (suspected or confirmed)
  5. Respiratory distress presumed secondary to an etiology other than RDS (e.g., suspected pulmonary hypoplasia, pneumothorax, meconium aspiration syndrome, pneumonia, septic or hypovolemia shock, hypoxic ischemic encephalopathy)
  6. Apgar score \< 3 at 5 minutes of age
  7. Umbilical cord gas pH \<7.0 or BD > 10
  8. Any condition that, in the opinion of the Investigator, would place the neonate at undue risk
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Treatment Arm

    A single dose of Calfactant at 6ml/kg administered via the Infasurf Aero™ Nebulizer until completion.

    Combination Product: Infasurf Aero™

  • Sham comparator
    Control Arm

    Low flow respiratory air alone through the InfasurfAero™ Nebulizer until completion.

    Combination Product: Infasurf Aero™

Interventions

  • Combination productInfasurf Aero™

    A single dose of Calfactant administered by pacifier interface by inhalation via the Infasurf Aero nebulizer at 6ml/kg.

06

What researchers measure

Primary outcomes

  1. CPAP failure and or death

    CPAP failure is defined as a respiratory severity score (RSS) (MAP x FiO2) \>2.5 on two consecutive assessments at least 30 minutes apart, or an RSS \> 2.4 and one or more of the following: (i) Silverman-Andersen respiratory severity score (https://www.thecalculator.co/health/Silverman-Score-Calculator-1125.html) of ≥ 5 despite respiratory support. (ii) Severe apnea (2 or more episodes per hour, or 1 or more episodes requiring manual positive pressure ventilation). (iii) Respiratory acidosis (pCO2 \> 65 with a pH \< 7.2 on blood gas). RSS will be the primary indicator of CPAP failure. However with the addition of the Silverman-Anderson scores, severe apnea and respiratory acidosis, CPAP failure may occur earlier than solely defined by RSS score.

    Time frame: Within 1st week of age

Secondary outcomes

  1. Chronic lung disease and or death

    Chronic lung disease is defined as altitude adjusted oxygen requirement at 36 weeks post menstrual age.

    Time frame: 36 weeks post menstrual age (PMA).

  2. Incidence of MV

    Incidence of Mechanical Ventilation

    Time frame: 36 weeks PMA

  3. Duration of MV

    length of time of Mechanical Ventilation

    Time frame: 36 weeks PMA

  4. Incidence of intubation

    Any occurrence of tracheal intubation

    Time frame: 36 weeks PMA

  5. Incidence of invasive surfactant replacement therapy

    any occurrence of liquid surfactant administration via and endotracheal tube

    Time frame: 72 hours post birth

  6. Duration of non-invasive support

    Length of time of respiratory support other than Intubation

    Time frame: 36 weeks PMA

  7. Duration of supplemental oxygen

    Length of time any oxygen is administered.

    Time frame: 36 weeks PMA

Other outcomes

  1. Adverse events during surfactant administration.

    Incidence of bradycardia and desaturation during surfactant administration.

    Time frame: Birth to 72 hours of age.

07

Study locations

10 of 10 sites recruiting
  • St. Josephs Hospital and Medical Center
    Phoenix, Arizona 85013, United States
    Recruiting
  • Phoenix Children's
    Phoenix, Arizona 85016, United States
    Recruiting
  • Sharp Mary Birch Hospital for Women & Newborns
    San Diego, California 92123, United States
    Recruiting
    • Alona Diem · ContactAlona.Diem@sharp.com] · 858-939-4301
    • Anup Katheria, MD · Principal investigator
  • University of Florida -Jacksonville
    Jacksonville, Florida 32209, United States
    Recruiting
  • Kapi'olani Medical Center for Women & Children
    Honolulu, Hawaii 96826, United States
    Recruiting
  • Jersey Shore University Medical Center
    Neptune, New Jersey 07753, United States
    Recruiting
  • Sisters of Charity Hospital
    Buffalo, New York 14214, United States
    Recruiting
    • George Albert, MD · Contact716-862-1000
    • George Albert, MD · Principal investigator
  • Western TN- Jackson-Madison County General Hospital
    Jackson, Tennessee 38301, United States
    Recruiting
    • Laura Choate, BSN · Contactlaura.choate@wth.org · (731) 541-5000
    • Scott Guthrie, MD · Sub investigator
    • Stacy Slagle, MD · Principal investigator
  • Utah Valley Hospital
    Provo, Utah 84604, United States
    Recruiting
    • Jennifer Elmont · ContactJennifer.Elmont@imail.org · 801-507-7036
    • Steven Minton, MD · Principal investigator
    • Erick Gerday, MD · Principal investigator
  • Unity Point Meriter
    Madison, Wisconsin 53715, United States
    Recruiting
    • Shayla Schwingle Study Coordinator · Contactsnschwingle@wisc.edu · (608) 417-6000
    • Dinushuan Kaluarachchi, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Jan 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2023
First posted
Jul 27, 2023
StartActual
Jan 1, 2025
Primary completionEst.
Jan 1, 2026
CompletionEst.
Apr 1, 2026
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05960929
Lead sponsor
ONY
Collaborators
Avania
Responsible party
Sponsor
First posted
Jul 27, 2023
Start date
Jan 1, 2025
Primary completion
Jan 1, 2026 (estimated)
Completion
Apr 1, 2026 (estimated)
Last update
Mar 30, 2025

Study contacts

Corey Commaroto, RRT
Contact
ccommaroto@onybiotech.com
7163614659
Dan Swartz, PhD
Contact
dswartz@onybiotech.com
716428-3132
Scott Guthrie, MD
study chair · Vanderbilt Jackson-Madison, Jackson TN
Dinushan Kaluarachchi, MD
study chair · Unity Point Meriter, Madison WI
Jim Cummings, MD
study director · Ony Biotech

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion